Clinical trial
Safety Study to Evaluate FluMist in Immunocompromised Children
NCT00112112 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00112112 |
|---|---|
| Title | Safety Study to Evaluate FluMist in Immunocompromised Children |
| Official title | A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of Age |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Biological |
| Interventions | FluMist, Placebo |
| Enrollment | 20 |
| Start date | Aug 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | May 1, 2008 |
| First posted | May 30, 2005 |
| Last update posted | Aug 14, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: